OSCAR Study lessons – «EpidemiOlogy and treatment of high-riSk patients in real-world ClinicAl pRactice, 2005-2006»
Aim. To present the results of OSCAR‑2006 therapeutic program; to discuss lipid‑lowering therapy effectiveness in real‑world clinical practice. Material and methods. In total, the study included 7098 patients, with more than 50% suffering from verified (86,8%) coronary heart disease (CHD). The progr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2007-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim. To present the results of OSCAR‑2006 therapeutic program; to discuss lipid‑lowering therapy effectiveness in real‑world clinical practice. Material and methods. In total, the study included 7098 patients, with more than 50% suffering from verified (86,8%) coronary heart disease (CHD). The program was educational: patients did not receive free simvastatin or atorvastatin for 8 weeks, but were persuaded to take the medications purchased by themselves. Results. After 8‑week statin therapy (atorvastatin), the levels of total cholesterol (TCH) were reduced by 22,7%, low‑density CH (LDL‑CH) ‑ by 26,7%, and triglycerides – by 24,0%. Treatment effectiveness (achieving target LDL‑CH levels <2,6 mmol/l) increased from 4,3% to 17,0%. Lipid and blood pressure reduction resulted in total cardiovascular risk decrease by 33%. OSCAR Study results are also promising in regard to statin safety. During the study, only 195 (2,7%) adverse events were registered. Conclusion. In a large‑scale, real‑world clinical practice study, the perspectives of risk factor control by using medications improving life prognosis were demonstrated. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |